Loading
Depression in Adolescence / MagPro X100 edition (MagVenture, Skovlunde, Denmark) / Depression · Interventional Study
ClinicalTrials.gov · August 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This registry record describes a planned single-site, open-label feasibility trial of accelerated intermittent theta burst stimulation (aiTBS) in treatment-naive adolescents with first-episode major depression. No results have been reported; the study is currently recruiting. The uncontrolled design and small sample size mean findings, when available, will be preliminary only.
Interventional, Randomized, Parallel, Single masking, Treatment purpose. Major Depressive Disorder, Depression in Adolescence, Depression, Major Depressive Episode; age from 13 Years; to 20 Years. Intervention: Half-Dose paiTBS. Compared with: Full-Dose paiTBS — Active Comparator. n = 40. 1 site: United States.
This registry record describes a planned single-site, open-label feasibility trial of accelerated intermittent theta burst stimulation (aiTBS) in treatment-naive adolescents with first-episode major depression. No results have been reported; the study is currently recruiting. The uncontrolled design and small sample size mean findings, when available, will be preliminary only.
Small sample size (estimated 40) is underpowered for definitive efficacy or safety conclusions.
This trial is at an early feasibility stage and cannot yet inform clinical practice. Once results are published, the open-label design and lack of a control group will limit the strength of evidence; a comparator or sham-control arm would be needed to support efficacy claims.
This is a registry record for a single-site, open-label, uncontrolled feasibility trial with an estimated 40 participants; no results are reported, and the design lacks a comparator arm, making it preliminary.
As stated by the source record.
Quoted from the source exactly as published.
This trial is at an early feasibility stage and cannot yet inform clinical practice. Once results are published, the open-label design and lack of a control group will limit the strength of evidence; a comparator or sham-control arm would be needed to support efficacy claims.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06523439). This is a study registration, not published results. Lead sponsor: University of Texas at Austin. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 40 participants (ESTIMATED). Conditions: Major Depressive Disorder, Depression in Adolescence, Depression, Major Depressive Episode. Interventions: DEVICE: MagPro X100 edition (MagVenture, Skovlunde, Denmark); DEVICE: MagPro X100 edition (MagVenture, Skovlunde, Denmark). Primary outcome measures: Childhood Depression Rating Scale-Revised (CDRS-R) Remission Rates , Baseline, One Month Follow Up Visit; Childhood Depression Rating Scale-Revised (CDRS-R) Remission Rates , Baseline, One Month Follow Up Visit. Brief summary: This is a single-site open-label clinical trial of fMRI-guided accelerated intermittent theta burst stimulation. The goal of this clinical trial is to learn if a new form of transcranial magnetic stimulation (TMS)-known generally as accelerated intermittent theta burst stimulation (aiTBS)-is effective as a first-line therapy in treating adolescents aged 13-20 years-old in their first episode of depression who have not undergone a full course of depression treatment prior to starting the trial and who remain antidepressant-free throughout the trial. The main questions this trial aims to answer are: * Does aiTBS relieve symptoms of depression as a first-line therapy in adolescents? * Is aiTBS a feasible option as a first-line treatment for adolescent depression? Researchers will measure the depression symptoms in adolescent participants before and after aiTBS. Parents of the adolescent participant will also participate in the study providing information about their experience and preference for TMS as a first-line treatment. Adolescent participants will: * Remain antidepressant-free throughout the study period of 6-7 weeks. * Receive an fMRI of their head for precision targeting * Receive 5 days of aiTBS
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.